Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Fotini Vogiatzi, PhD, Kristina Müller, Dorothee Winterberg, Thies Rösner, PhD, Lennart Lenk, PhD, Gunnar Cario, MD PhD, Martin Schrappe, MDPhD, Andreas E. Kulozik, MD PhD, Beat Bornhauser, Jean-Pierre Bourquin, MD PhD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140270

Published: 2020

Journal Articles

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

Judith Petersen, Thies Rösner, PhD, Max Kölling, Katja Klausz, PhD, Christian Kellner, PhD, Andreas Humpe, MD, George J Weiner, MD, Denis Martin Schewe, Matthias Peipp, PhD, Thomas Valerius, MD

Blood (2019) 134 (Supplement_1): 5305.

https://doi.org/10.1182/blood-2019-122940

Published: 2019

Journal Articles

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

Fotini Vogiatzi, PhD, Julia Heymann, Thies Rösner, PhD, Lennart Lenk, PhD MSc, Gunnar Cario, MD, Martin Schrappe, MD PhD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD, Simon Bomken, MD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2018) 132 (Supplement 1): 4177.

https://doi.org/10.1182/blood-2018-99-114677

Published: 2018

Journal Articles

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

Thorsten Ross, PhD, Uwe Reusch, PhD, Susanne Wingert, PhD, Torsten Haneke, PhD, Katja Klausz, PhD, Anna-Kathrin Otte, PhD, Natalie Schub, MD, Stefan Knackmuss, PhD, Thomas Müller, Kristina Ellwanger, PhD, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, PhD, Thomas Valerius, MD, Martin Gramatzki, MD, Matthias Peipp, PhD, Michael Tesar, PhD, Erich Rajkovic, PhD MBA, Martin Treder, PhD

Blood (2018) 132 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2018-99-118970

Published: 2018

Journal Articles

CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells

Anna Kretschmer, Stefan Lohse, PhD, Thies Rösner, PhD, Marco J.H. Jansen, Christian Kellner, PhD, Matthias Peipp, PhD, Mark S Cragg, PhD, Ameera Alsadeq, PhD, Denis M Schewe, MD, Jeanette H.W. Leusen, PhD, Thomas Valerius, MD

Blood (2016) 128 (22): 1835.

https://doi.org/10.1182/blood.V128.22.1835.1835

Published: 2016

Journal Articles

An Fc-Engineered CD19 Antibody Engages Macrophages and Is Effective in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

Denis M Schewe, MD, Ameera Alsadeq, PhD, Gunnar Cario, MD, Simon Vieth, MD, Thomas Valerius, MD, Martin Schrappe, MD PhD, Martin Gramatzki, MD, Matthias Peipp, PhD, Christian Kellner, PhD

Blood (2016) 128 (22): 277.

https://doi.org/10.1182/blood.V128.22.277.277

Published: 2016

Journal Articles

Switching from IgG1 to IgG3 Isotype to Boost Complement-Activating Capacities of Therapeutic Antibodies – Impact of CD55 Expression on the Mode of Action

Stefanie Derer, PhD, Thies Rösner, Stefan Lohse, PhD, Matthias Peipp, PhD, Thomas Valerius, MD

Blood (2014) 124 (21): 3506.

https://doi.org/10.1182/blood.V124.21.3506.3506

Published: 2014

Journal Articles

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

Matthias Peipp, PhD, Christian Kellner, PhD, Andreas Günther, MD, Andreas Humpe, MD, Roland Repp, MD, Katja Klausz, PhD, Stefanie Derer, PhD, Thomas Valerius, MD, Jan G.J. van de Winkel, PhD, Paul W.H.I. Parren, PhD, Martin Gramatzki, MD

Blood (2014) 124 (21): 1779.

https://doi.org/10.1182/blood.V124.21.1779.1779

Published: 2014

Journal Articles

Analyses of a Pair of Concordant Twins with Infant ALL and Discordant Clinical Outcome Reveals Immunoescape As a Mechanism of Disease Persistence in MLL-Rearranged Leukemia

Henning Fedders, PhD, Ameera Alsadeq, PhD, Britt-Sabina Petersen, PhD, Christian Kellner, PhD, Matthias Peipp, PhD, Thomas Valerius, MD, Robert Haesler, PhD, Julia Alten, MD, Anja Möricke, Susanne Strube, PhD, Thomas Wiesel, MD, Gunnar Cario, MD, Martin Schrappe, Andre Franke, PhD, Martin Stanulla, MD, Denis Martin Schewe, MD

Blood (2014) 124 (21): 3791.

https://doi.org/10.1182/blood.V124.21.3791.3791

Published: 2014

Journal Articles

Ratios Of FcγRIIa and FcγRIII Binding Affinities Govern The Efficacy Of PMN-Mediated Cytotoxicity – Implications For Fc-Engineering Approaches Of Therapeutic Antibodies

Stefanie Derer, PhD, Pia Glorius, PhD, Martin Schlaeth, Stefan Lohse, PhD, Umesh Muchhal, Ph.D., John Desjarlais, Andreas Humpe, MD, Thomas Valerius, MD, Matthias Peipp, PhD

Blood (2013) 122 (21): 3466.

https://doi.org/10.1182/blood.V122.21.3466.3466

Published: 2013

Journal Articles

Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.

Michael Dechant, MD, Stefan Lohse, PhD, Stefanie Derer, PhD, Thomas Beyer, PhD, Katja Klausz, PhD, Matthias Peipp, PhD, Jeanette H. W. Leusen, PhD, Jan G. J. van de Winkel, PhD, Thomas Valerius, MD

Blood (2010) 116 (21): 1488.

https://doi.org/10.1182/blood.V116.21.1488.1488

Published: 2010

Journal Articles

Recombinant Chimeric IgA1 and IgA2 Antibodies for Tumor Immunotherapy.

Michael Dechant, MD, Thomas Beyer, PhD, Stefan Lohse, Tanja Schneider-Merck, PhD, Wencke Weisner, Sven Berger, PhD, Matthias Peipp, PhD, Jan G.J. van de Winkel, PhD, Thomas Valerius, MD

Blood (2007) 110 (11): 4892.

https://doi.org/10.1182/blood.V110.11.4892.4892

Published: 2007

Journal Articles

A Humanized HLA-DR Antibody (HU1D10, Apolizumab) in Combination with G-CSF (Filgrastim) for the Treatment of Non-Hodgkin’s Lymphoma: A Pilot Study.

Juergen Rech, MD, Roland Repp, MD, Dorit Rech, MD, Bernhard Stockmeyer, MD, Michael Dechant, MD, Gerald Niedobitek, MD, Tilman Pearce, MD, Georg Weiner, MD, Martin Gramatzki, MD, Thomas Valerius, MD.

Blood (2005) 106 (11): 4775.

https://doi.org/10.1182/blood.V106.11.4775.4775

Published: 2005

Journal Articles

Fully Human CD38 Antibodies Efficiently Trigger ADCC of Multiple Myeloma Cell Lines and Primary Tumor Cells.

Matthias Peipp, PhD, Michel de Weers, PhD, Thomas Beyer, PhD, Roland Repp, MD, Paul Parren, PhD, Thomas Valerius, MD, Jan G.J. van de Winkel, PhD

Blood (2005) 106 (11): 3377.

https://doi.org/10.1182/blood.V106.11.3377.3377

Published: 2005

NARROW

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells

An Fc-Engineered CD19 Antibody Engages Macrophages and Is Effective in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

Switching from IgG1 to IgG3 Isotype to Boost Complement-Activating Capacities of Therapeutic Antibodies – Impact of CD55 Expression on the Mode of Action

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

Analyses of a Pair of Concordant Twins with Infant ALL and Discordant Clinical Outcome Reveals Immunoescape As a Mechanism of Disease Persistence in MLL-Rearranged Leukemia

Ratios Of FcγRIIa and FcγRIII Binding Affinities Govern The Efficacy Of PMN-Mediated Cytotoxicity – Implications For Fc-Engineering Approaches Of Therapeutic Antibodies

Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.

Recombinant Chimeric IgA1 and IgA2 Antibodies for Tumor Immunotherapy.

A Humanized HLA-DR Antibody (HU1D10, Apolizumab) in Combination with G-CSF (Filgrastim) for the Treatment of Non-Hodgkin’s Lymphoma: A Pilot Study.

Fully Human CD38 Antibodies Efficiently Trigger ADCC of Multiple Myeloma Cell Lines and Primary Tumor Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only